Literature DB >> 21350358

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

Silvia Nozza, Laura Galli, Alba Bigoloni, Gianotti Nicola, Manuela Pogliaghi, Francesca Cossarini, Stefania Salpietro, Andrea Galli, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350358     DOI: 10.1097/QAI.0b013e31820a9ae4

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  4 in total

1.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

2.  Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.

Authors:  Valérie Potard; Jacques Reynes; Tristan Ferry; Céline Aubin; Laurent Finkielsztejn; Yazdan Yazdanpanah; Dominique Costagliola
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

3.  Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.

Authors:  Amit C Achhra; Mark A Boyd
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

4.  Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Authors:  Amit C Achhra; Mark A Boyd; Matthew G Law; Gail V Matthews; Anthony D Kelleher; David A Cooper
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.